Navigation Links
ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
Date:1/27/2010

CAMBRIDGE, Mass. and OXFORD, England, Jan. 27 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute and Oxford BioMedica (LSE: OXB) announced today the extension of their collaboration following successful completion of the first phase. The extended collaboration, which is funded by the Muscular Dystrophy Association, aims to advance the development of Oxford BioMedica's preclinical gene therapy candidate, MoNuDin®, and to evaluate other gene-based strategies for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

"ALS is a debilitating disease that takes so many of our best and brightest from us without warning and without reason. This collaboration adds yet another important element to our burgeoning drug development pipeline. Gene therapy is a crucial, emerging therapeutic option for diseases such as ALS and Oxford BioMedica has the experience and commitment for excellence needed in a partner,"  said Steven Perrin, Ph.D., Chief Executive Officer and Chief Scientific Officer of the ALS Therapy Development Institute (ALS TDI).

The collaboration combines Oxford BioMedica's advanced LentiVector® gene delivery technology with the ALS TDI's extensive gene expression database and drug screening capabilities. The first phase of the collaboration included the development of new techniques to evaluate and identify gene therapy candidates at the ALS TDI's research facility in Cambridge.

In this second next phase, the ALS TDI will conduct preclinical efficacy studies of Oxford BioMedica's LentiVector-based product, MoNuDin, which is designed to protect the motor neurons susceptible to degeneration from ALS by targeted delivery of the neuroprotective gene, vascular endothelial growth factor.  Furthermore, the joint team plans to evaluate other potentially therapeutic genes that inhibit or regulate specific genetic pathways associated with disease onset or progression.

Oxford BioMedica's Chief Executive Officer, John Dawson, commented: "The successful completion of the first phase of the collaboration is testament to the quality of the scientific teams at the ALS TDI and Oxford BioMedica. Our LentiVector technology has unique capabilities to deliver genes safely and efficiently to neuronal cells and our product candidate, MoNuDin, has shown promising results in preclinical models of ALS. The extension of our collaboration with the ALS TDI enables us to accelerate MoNuDin's development and to explore new disease pathways as potential targets for genetic intervention. We are delighted to have ongoing support from the Muscular Dystrophy Association for our collaboration with the ALS TDI, which underscores our shared goal to develop new treatment options for patients suffering from ALS."

The Muscular Dystrophy Association's Augie's Quest Initiative is a major donor to the ALS TDI and provided the critical funding needed to execute the collaboration between Oxford BioMedica and the ALS TDI.

About ALS TDI

The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), as soon as possible.  Focused on meeting this urgent unmet medical need, ALS TDI executes a robust discovery program, while running the world's largest efforts to pre-clinically validate potential therapeutics; including small molecules, protein biologics, gene therapies and cell-based constructs.  The world's first non-profit biotech, ALS TDI has developed an industrial-scale platform that allows for the development and testing of dozens of potential therapeutics each year.  Built by and for patients, the Institute is the world's only non-profit biotechnology company with more than 30 professional scientists. In addition, the Cambridge, Massachusetts based research Institute collaborates with leaders in both academia and industry.  For more information, please visit us online at www.als.net.

About Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline. Partners include sanofi-aventis, Sigma-Aldrich and Pfizer. Technology licensees include Biogen-Idec, GlaxoSmithKline, Merck & Co and Pfizer. Further information is available at www.oxfordbiomedica.co.uk.

About MDA

MDA (www.mda.org) is the world's largest nonprofit provider of ALS services and funder of ALS research. Over the years, MDA has invested $250 million specifically fighting ALS.  MDA operates more than 200 clinics at hospitals across the country, 36 of which are ALS-specific research and care centers.  The Association's unparalleled health care services, research, advocacy and education programs provide help and hope to more than one million Americans affected by ALS and 42 other neuromuscular diseases.

About Augie's Quest

Fitness pioneer Augie Nieto started Augie's Quest (www.augiesquest.org) in conjunction with MDA's ALS Division. Nieto is co-founder and former president of Life Fitness of Chicago, and chairman of Octane Fitness. He and his wife, Lynne, serve as co-chairpersons of MDA's ALS Division. Nieto received a diagnosis of ALS in March 2005, and Augie's Quest raises money primarily through a variety of special events, including "Fight Night" in Tustin, CA; Augie's Quest Bash in San Diego, CA; "Tradition of Hope" in Los Angeles, CA; "Celebrity Golf Classic" in Phoenix, AZ; "Gift of Time: St. Patty's Day Bash" in Denver, CO; "Field of Hope Gala" in New Jersey; "Secure A Cure Golf Classic" in Purchase, NY; "Big Canyon Golf" in Newport Beach, CA; The ClubCorp Charity Classic at golf clubs nationwide; plus "Clubs for A Cure" special visitation benefits for Augie's Quest at LA Fitness and Bally Total Fitness locations across the country, as well as at scores of other independent and regional health clubs.

SOURCE ALS Therapy Development Foundation

RELATED LINKS
http://www.als.net
http://www.oxfordbiomedica.co.uk/
http://www.mda.org/
http://www.augiesquest.org/

'/>"/>

SOURCE ALS Therapy Development Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
3. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
4. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
5. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
6. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
7. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
8. Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO
9. Stem Cell Therapy to Skyrocket by 2017
10. Team demos safety of RNA therapy
11. First European IGRT School Takes Place for Radiotherapy Practitioners in UK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... Clinovo ... free and validated Electronic Data Capture (EDC) system ClinCaptureand its new Contract Research ... West Coast 2016 Conference in San Mateo, California on February 10th and 11th. ...
(Date:2/9/2016)... ... 2016 , ... The American Academy of Thermology (AAT) has announced ... AAT Member Certification Qualification Course for Technicians via a two part webinar on July ... a detailed review of hardware, software, and camera setup/operations, aligns with the in-person member ...
(Date:2/9/2016)... ... February 09, 2016 , ... PharmApprove ... for the National Organization for Rare Disorders (NORD). Dorman will lead PharmApprove efforts ... are heard throughout the drug regulatory review process. , “Adding Diane Dorman is ...
(Date:2/9/2016)... YORK , Feb. 9, 2016 This ... analyzes the current and future prospects of the market ... this report include companies engaged in the manufacture of ... an executive summary with a market snapshot providing the ... scope of this report. This section also provides the ...
Breaking Biology Technology:
(Date:2/9/2016)... LIVERMORE, Calif. , Feb. 9, 2016 Vigilant ... mobile license plate reader (LPR) to develop a lead in ... and commercially available LPR data to locate the suspect vehicle. ... details of the case have been omitted at the agency,s ... spokesperson for the agency explains, "Our victim was found deceased ...
(Date:2/4/2016)... , Feb. 4, 2016 The field ... one of the most popular hubs of the ... and other huge studies of human microbiota, have ... few years, the microbiome space has literally exploded ... research. This report focuses on biomedical aspects ...
(Date:2/3/2016)... LIVERMORE, Calif. , Feb. 3, 2016 ... Police Department in Missouri ... of license plate reader (LPR) data from Vigilant Solutions. ... a hit-and-run case in which the victim was walking out ... a parking space next to his vehicle, striking his ...
Breaking Biology News(10 mins):